Wanbury has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its manufacturing facility located at MIDC Industrial Area, Patalganga, Maharashtra, India and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is ‘No Action Indicated’ (NAI) with zero 483 observation.
Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
